{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-23-000127","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.966177+00:00","generated_at":"2026-06-12T12:45:57.925252+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Castle Biosciences Q2 revenue $50.1M (+44% YoY); raises FY 2023 guidance to at least $180M","bullets":["Q2 revenue $50.1M (+44% YoY); adjusted revenue $50.2M (+47%).","Total test reports 16,820 (+52%); DecisionDx-SCC +99%, TissueCypher +311%, IDgenetix +224%.","Net loss $(18.8)M includes $12.8M stock comp; adjusted EBITDA improves to $(5.3)M from $(11.2)M.","Raises 2023 revenue guidance to at least $180M from prior $170-180M.","Cash and investments $225.5M; net operating cash use improved to $3.8M from $9.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-23-000127","json":"https://secwatch.observer/filing/0001447362-23-000127.json","markdown":"https://secwatch.observer/filing/0001447362-23-000127.md","text":"https://secwatch.observer/filing/0001447362-23-000127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000127/0001447362-23-000127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000127/cstl-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T12:45:57.925252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b87805c4d07d839e6c5bb800b914634777d803d","claim":"CASTLE BIOSCIENCES INC reported second quarter and six months ended June 30, 2023 results: revenue $50.1 million, net income $(18.8) million. Guidance raised.","evidence_excerpt":"such filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Castle Biosciences Reports Second Quarter 2023 Results Q2 2023 revenue increased 44% over Q2 2022 to $50 million Q2 2023 total test reports increased 52% over Q2 2022 Raising full year 2023 revenue guidance to at least $180 million from $170-180 million Conference call and webcast today at","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000127/0001447362-23-000127-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter and six months ended June 30, 2023"},{"label":"Revenue","value":"$50.1 million"},{"label":"Net income","value":"$(18.8) million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}